Literature DB >> 8916629

Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study.

S M Hall1, R F Muñoz, V I Reus, K L Sees, C Duncan, G L Humfleet, D T Hartz.   

Abstract

Earlier research indicated that a 10-session mood management (MM) intervention was more effective than a 5-session standard intervention for smokers with a history of major depressive disorder (MDD). In a 2 x 2 factorial design, the present study compared MM intervention to a contact-equivalent health education intervention (HE) and 2 mg to 0 mg of nicotine gum for smokers with a history of MDD. Participants were 201 smokers, 22% with a history of MDD. Contrary to the earlier findings, the MM and HE interventions produced similar abstinence rates: 2 mg gum was no more effective than placebo. History-positive participants had a greater increase in mood disturbance after the quit attempt. Independent of depression diagnosis, increases in negative mood immediately after quitting predicted smoking. No treatment differences were found in trends over time for measures of mood, withdrawal symptoms, pleasant activities and events, self-efficacy, and optimism and pessimism. History-positive smokers may be best treated by interventions providing additional support and contact, independent of therapeutic content.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916629     DOI: 10.1037//0022-006x.64.5.1003

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  51 in total

1.  Design and pilot evaluation of an internet smoking cessation program.

Authors:  Leslie Lenert; Ricardo F Muñoz; Jackie Stoddard; Kevin Delucchi; Aditya Bansod; Steven Skoczen; Eliseo J Pérez-Stable
Journal:  J Am Med Inform Assoc       Date:  2003 Jan-Feb       Impact factor: 4.497

Review 2.  Do changes in mood and concerns about weight relate to smoking relapse in the postpartum period?

Authors:  M D Levine; M D Marcus
Journal:  Arch Womens Ment Health       Date:  2004-04-16       Impact factor: 3.633

3.  Depression vulnerability moderates the effects of cognitive behavior therapy in a randomized controlled trial for smoking cessation.

Authors:  Heather Schloss Kapson; David A F Haaga
Journal:  Behav Ther       Date:  2010-05-05

Review 4.  Behavioral therapies for co-occurring substance use and mood disorders.

Authors:  Kathleen M Carroll
Journal:  Biol Psychiatry       Date:  2004-11-15       Impact factor: 13.382

5.  Associations between Cloninger's temperament dimensions and acute tobacco withdrawal.

Authors:  Adam M Leventhal; Andrew J Waters; Susan Boyd; Eric T Moolchan; Stephen J Heishman; Caryn Lerman; Wallace B Pickworth
Journal:  Addict Behav       Date:  2007-06-09       Impact factor: 3.913

Review 6.  The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations.

Authors:  Jaimee L Heffner; Jeffrey R Strawn; Melissa P DelBello; Stephen M Strakowski; Robert M Anthenelli
Journal:  Bipolar Disord       Date:  2011 Aug-Sep       Impact factor: 6.744

7.  Relationship between momentary affect states and self-efficacy in adolescent smokers.

Authors:  Bettina B Hoeppner; Christopher W Kahler; Chad J Gwaltney
Journal:  Health Psychol       Date:  2014-07-14       Impact factor: 4.267

8.  Bupropion and cognitive-behavioral treatment for depression in smoking cessation.

Authors:  Richard A Brown; Raymond Niaura; Elizabeth E Lloyd-Richardson; David R Strong; Christopher W Kahler; Ana M Abrantes; David Abrams; Ivan W Miller
Journal:  Nicotine Tob Res       Date:  2007-07       Impact factor: 4.244

Review 9.  Smoking cessation: significance and implications for children.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

10.  Gender effects on mood and cigarette craving during early abstinence and resumption of smoking.

Authors:  Jiansong Xu; Allen Azizian; John Monterosso; Catherine P Domier; Arthur L Brody; Timothy W Fong; Edythe D London
Journal:  Nicotine Tob Res       Date:  2008-11       Impact factor: 4.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.